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October 9, 2012:1430–7completely occlude the ostium. The shape mismatch between
the LAA ostium and the device is clearly evidenced in the
three-dimensional transesophageal echocardiographic images,
such as the one included in our paper (1).
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New Oral Anticoagulants:
Good but Not Good Enough!
In the recent article by the European Society of Cardiology
Working Group on anticoagulants in heart disease (1), the authors
describe in great clarity the emerging data regarding new antico-
agulants for the treatment of nonvalvular atrial fibrillation. In the
closing segment of conclusions and implications, the authors list
their concerns regarding “scientific knowledge gaps” and the lack
of clinical tools (like reversal agents or pharmacodynamic moni-
toring objectives and means). Regrettably, in the name of simplic-
ity (i.e., no pharmacodynamic monitoring or dose adjustment and
rigid dose regimens with a one-size-fits-all strategy), we have
taken potentially great drugs and made them good, but truly not
good enough for some of our individual patients.
Why should we bother with pharmacodynamic studies of these
agents? Numerous known factors (body weight, age, renal func-
tion, liver function, Cyp 3A4, and P-glycoprotein inhibitors and
inducers) and probably many unknown factors interact with these
agents to create heterogeneous effect on plasma levels and coagu-
lation profile. Because these agents are meant to be lifelong
prescriptions, they probably command the effort of knowing how
the individual patient responds to the prescribed agent and dose.
This is especially true because we have the option of prescribing
alternative drugs and doses to suit the individual patient best.
Major bleeding is the most common complication of these
agents in patients with nonvalvular atrial fibrillation (exceeding in
most current studies the rate of clinical thromboembolism) and
probably can be reduced by individualized drug prescribing and
dosing based on individual pharmacokinetic and pharmacody-
namic studies. Further, thromboembolism and stroke possibly
related to therapeutic failure potentially can be reduced by moni-
toring and dose adjustments to enhance efficacy.Should we decide to extend the use of these agents to other
patient subsets (valvular atrial fibrillation, mechanical valves, hy-
percoagulable states), establishing monitoring protocols and delin-
eating the therapeutic targets may facilitate the design of future
clinical trials and may optimize both efficacy and safety. As an
example, in the PETRO (Prevention of Embolic and ThROm-
botic events study) among patients receiving dabigatran 150 mg
twice daily, there was an approximately 7-fold difference in
between the fifth and 95th percentile in both peak (95% confidence
interval: 64 to 443 ng/ml) and trough (95% confidence interval: 31
to 225 ng/ml) plasma levels (2). This 7-fold difference translates
into significantly higher exposure, thrombin time, and bleeding
risk. On the other end of the spectrum, approximately 15% of the
patients had peak activated partial thromboplastin time of 40 s.
Future research should attempt to delineate: 1) the best phar-
macodynamic monitoring tools for dabigatran (2) and Xa inhibi-
tors (3,4); 2) the best monitoring protocol (5) (including timing
relative to dosing and frequency); and 3) the best therapeutic
targets. It is very likely that by using these strategies, we could
enhance further the efficacy and safety of these agents and could
extend their use to new indications.
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Reply
We thank Dr. Kaluski and colleagues for their thoughts on the
possibility of individualizing dosing strategies for the new oral
anticoagulants. From a theoretical perspective, the one-size-
fits-all strategy seems not to be ideal, because of the potential
pharmacokinetic interactions, the variability in drug metabo-
lism during lifelong administration, and the inherent risks of
thrombosis in the case of underdosing or of bleeding in the case
of overdosing. For this reason, we favored the European
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etexilate studied in RE-LY (150 mg twice daily and 110 mg
twice daily), and also the U.S. Food and Drugs Administration
policy of recommending the even lower 75 mg twice daily dose
in selected conditions of poor renal function (1). Also for the
factor (F)Xa-inhibitors rivaroxaban and apixaban, a lower dose
has been used in the trials in selected conditions of poor renal
function and is recommended in the current or forthcoming
labels. In the phase III trial of the FXa inhibitor edoxaban in
nonvalvular atrial fibrillation, 2 exposure strategies and 3 dosing
regimens were tested to obtain a more personalized treatment
approach. Such trial design leads to the need for a very large
patient sample size in the pivotal phase III trial, which has not
always been possible because it is forbiddingly expensive. A
more feasible approach may be to test alternative dosing
regimens after regulatory approval, that is, in the context of
simple trials in a registry-like environment. This will allow a
firmer documentation of the best regimens and a considerably
more valid background than basing the choice of alternative
regimens only on pharmacokinetic considerations. Still, there is
no evidence that an individualized regimen with frequent
monitoring and dose changes is either safer or more effective
than a standard dose regimen, especially when using medica-
tions with a wider therapeutic window than vitamin K antag-
onists.
We very much warn against the proposal in the letter to extend
the clinical use of these new treatments to patients with mechanical
valves or hypercoagulable states based only on pharmacokinetic
considerations, other than in the design of real efficacy trials.
Patients with these diseases may well require drug dosing regimens
different from those evaluated so far in clinical trials. Specific
efficacy trials in these new settings are needed, and actually already
have begun.
We certainly agree with a plea for prudence in the use of these
new drugs, for which simplicity of use—undoubtedly much higher
than for vitamin K antagonists—may create the illusion of absence
of problems, which is certainly not the case.
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The Use of 18F-FDG-PET/CT
in the Diagnostic Workup
of CIED Infections:
Another Perspective
We read with great interest the article by Sarrazin et al. (1) on the
use of 18F-fluorodeoxyglucose (FDG)–positron emission tomog-
raphy (PET)/computed tomography (CT) in the diagnostic
workup of suspected cardiovascular implantable electronic device
(CIED) infections. This study indeed has great clinical potential.
In fact, as noted in the accompanying editorial (2), clinicians will
greatly benefit from a highly accurate diagnostic procedure to
confirm CIED infection, evaluate its extent, and guide the decision
whether to remove the device versus treating patients with antimi-
crobial treatment alone.
However, such an ambitious task will require more of a
problem-solving approach than a single test assessment. There-
fore, we believe that some comments may shed new light on the
findings of Sarrazin et al. (1). The authors indicated 88.6%
sensitivity and 85.7% specificity of 18F-FDG-PET/CT, the
latter increasing to 100% when a specific interpretation criterion
(abnormal/lung 18F-FDG uptake ratio 1.87) was applied.
Considering that the authors performed 18F-FDG-PET/CT in
patients with a high pre-test probability, the false positive rate
may be underestimated in this series. Therefore, such high
specificity is achievable by adopting accurate patient selection
and inclusion criteria. Indeed, the application of 18F-FDG-
PET/CT in patients with lower pre-test probability will rely on
the high negative predictive value of the technique. In fact, up
to 8% of false-positive findings has been reported in patients
with pacing systems without signs of infection (3). For lower-
risk patients, higher-specificity techniques such as 99mTc–
hexamethylpropyleneamine oxime–leukocyte single-photon
emission CT (SPECT)/CT, as recently reported for infective
endocarditis (4), might be considered. In this regard, the
general notion of the lower spatial resolution for SPECT/CT
compared with PET/CT should consider improvements achiev-
able with current-generation hybrid SPECT/spiral CT scanner
(5,6). Finally, specific information about the type of microor-
ganisms and data on concomitant antimicrobial treatment,
particularly on the type of agents and their activity on biofilm
formation (7), will help in the understanding of false-negative
rates (4 cases in this paper) and therefore estimation of
limitations of the test. For example, as also mentioned in the
editorial, microorganisms such as Enterococcus and Candida have
the ability to elude leukocyte recruitment (8,9), possibly affect-
ing PET/CT results. Additionally, because this paper stated
that 42% of patients with limited superficial skin infections at
PET scan were treated with antimicrobial agents only, a higher
rate as compared with the recommendation for CIED removal
(10), the evaluation of microbiological results in this subgroup
is critical. Considering the low rate of negative CIED pocket
